Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1784458 | 0.84 | TP53 (0.46) | SIGMAR1TP53DDB1CRBNMAPT | |
| SCHEMBL1786072 | 0.84 | HTR2C (0.52) | SIGMAR1TP53DDB1CRBNMAPT | |
| SCHEMBL10061751 | 0.83 | HTR2C (0.43) | SIGMAR1MEN1KMT2AMAPTKIF11 | |
| SCHEMBL18419679 | 0.80 | SIGMAR1 (0.39) | SIGMAR1MEN1KMT2ATP53DDB1 | |
| SCHEMBL12251567 | 0.80 | TP53 (0.42) | SIGMAR1TP53DDB1CRBNMAPT | |
| SCHEMBL4597601 | 0.80 | MAPT (0.41) | SIGMAR1MEN1KMT2ATP53MAPT | |
| SCHEMBL7827695 | 0.80 | MAPT (0.41) | SIGMAR1MEN1KMT2ATP53MAPT | |
| SCHEMBL21208433 | 0.80 | MAPT (0.41) | SIGMAR1MEN1KMT2ATP53MAPT | |
| SCHEMBL7050263 | 0.80 | MAPT (0.41) | SIGMAR1MEN1KMT2ATP53MAPT | |
| SCHEMBL7050271 | 0.80 | PNMT (0.48) | MAPTKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411390-A1 | MODULATION OF BACTERIAL QUORUM SENSING WITH SYNTHETIC LIGANDS | WISCONSIN ALUMNI RES FOUND (US) | 2022-12-29 | — | — | US | disclosed |
| EP-3772517-B1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING SAME, AND DIAGNOSTIC COMPOSITION INCLUDING SAME | SAMSUNG ELECTRONICS CO LTD (KR) | 2022-11-02 | — | — | EP | disclosed |
| WO-2022140472-A1 | COMPOUNDS FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEOSOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| EP-3943087-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2022-01-26 | — | — | EP | disclosed |
| WO-2021191391-A1 | AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | WO | disclosed |
| US-20200231588-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. | 2020-07-23 | — | — | US | disclosed |
| US-10689378-B2 | Triazolopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2020-06-23 | — | — | US | disclosed |
| US-10689378-B2 | Triazolopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2020-06-23 | — | — | US | disclosed |
| US-10645928-B2 | Pesticidally active polycyclic derivatives with sulfur containing substituents | SYNGENTA PARTICIPATIONS AG (CH) | 2020-05-12 | — | — | US | disclosed |
| EP-3472161-B1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2020-03-25 | — | — | EP | disclosed |
| US-5244912-A | Serotonin antagonist | ELI LILLY AND COMPANY (US) | 1993-09-14 | — | — | US | disclosed |
| US-5244911-A | Serotonin antagonist | ELI LILLY AND COMPANY (US) | 1993-09-14 | — | — | US | disclosed |
| US-5229410-A | 6-substituted-hexahydrobenz[cd]indoles | ELI LILLY AND COMPANY (US) | 1993-07-20 | — | — | US | disclosed |
| US-5229409-A | Antidepressant, tranquilizer | ELI LILLY AND COMPANY (US) | 1993-07-20 | — | — | US | disclosed |
| EP-0506363-A1 | 6-Heterocyclic-4-amino-1,3,4,5-tetrahydrobenz[cd]indoles | ELI LILLY AND COMPANY (US) | 1992-09-30 | — | — | EP | disclosed |
| EP-0506369-A1 | 6-Heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz[CD]indoles | ELI LILLY AND COMPANY (US) | 1992-09-30 | — | — | EP | disclosed |
| EP-0471569-A1 | 6-Substituted-hexahydrobenz (CD) indoles | ELI LILLY AND COMPANY (US) | 1992-02-19 | — | — | EP | disclosed |
| EP-0471515-A1 | Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes, 3-aminochromanes and 3-aminothiochromanes | ELI LILLY AND COMPANY (US) | 1992-02-19 | — | — | EP | disclosed |
| EP-0471576-A1 | 6-substituted-tetrahydrobenz[cd]indoles | ELI LILLY AND COMPANY (US) | 1992-02-19 | — | — | EP | disclosed |
| EP-0444854-A2 | 6-Substituted hexahydrobenz[cd]indoles | ELI LILLY AND COMPANY (US) | 1991-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10645928-B2 | Pesticidally active polycyclic derivatives with sulfur containing substituents | DDT, SQOR, ACHE | SIGMAR1 1153/4885MEN1 874/4885KMT2A 2395/4885 |
| US-20220411390-A1 | MODULATION OF BACTERIAL QUORUM SENSING WITH SYNTHETIC LIGANDS | AHCYL1, EBPL, AIP | SIGMAR1 2319/4885MEN1 4259/4885KMT2A 2147/4885 |
| US-20200231588-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | SIGMAR1 1638/4885MEN1 244/4885KMT2A 2113/4885 |
| US-10689378-B2 | Triazolopyridine compounds and uses thereof | EZH2, EED, BMI1 | SIGMAR1 2831/4885MEN1 1452/4885KMT2A 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.